The Bonnie J. Addario Lung Cancer Foundation and Cancer Commons Partner to Help Patients Find Their Best Treatment Options

ALCF-vertical-logo-300x378

CC-BC-logo (1)

Patients Share Their Lung Cancer Experiences and Data to Get Personalized Treatment Guidance   

SAN CARLOS, Calif. and PALO ALTO, Calif. (April 21, 2014)– The Bonnie J. Addario Lung Cancer Foundation (ALCF) and Cancer Commons today announced the launch of a new program called MyCancerCommons, created to make sure critical lung cancer treatment information reaches the patients who need it. Continue reading…


Marty Tenenbaum to Speak at ALCF Lung Cancer Living Room, April 22

Cancer Commons founder Marty Tenenbaum will be the guest speaker at the Bonnie J. Addario Lung Cancer Foundation’s (ALCF) monthly Lung Cancer Living Room event on Tuesday, April 22. Marty’s own cancer diagnosis and treatment journey inspired his current mission: to make sure critical information is shared and gets to the patients who need it. By collecting data from thousands of patient-donated lung cancer stories, Cancer Commons can begin to show patients and doctors patterns in treatment choices, side effects, quality of life, outcomes, and more.

The ALCF, one of our partner organizations, works directly with individual lung cancer patients to ensure they each receive the best possible care. The Lung Cancer Living Room is a monthly in-person and online support group event that informs patients about lung cancer.

Click here for more information, including how to attend in person (in San Carlos, CA) or online. Click here to read the description of Marty’s upcoming event.


Big Data Meets Cancer: Netflix CPO Neil Hunt Explains Why Cancer Commons Matters in TEDx Talk

Late last year, Netflix Chief Product Officer and Cancer Commons supporter Neil Hunt gave a talk at TEDxBeaconStreet. He believes that big data analysis outside of traditional clinical trials can help identify personalized treatments for individual patients that can significantly improve their chances of survival. As Hunt explains, Cancer Commons is an exciting embodiment of this new approach to life-saving cancer research. Watch the video:


NPR Covers Cancer Commons

CommonHealth, a blog affiliated with Boston’s NPR news station WBUR, recently posted an interview with Cancer Commons founder Marty Tenenbaum. Reporter Rachel Zimmerman caught up with Marty after a talk he gave at MIT in Cambridge. Marty told her his personal story, explained why Cancer Commons is collecting stories from other patients, and placed Cancer Commons’ efforts in the context of rapidly evolving understanding of the science behind cancer.

A quote from Marty: ” ‘We’re patient focused and science based; Our mission is to aggregate and analyze data, to provide patients with the best information — up-to-the-moment, personalized, and actionable to help them make informed decisions…like a Lonely Planet guide to cancer.’ ”

Read the full post here: http://commonhealth.wbur.org/2014/02/can-we-use-the-crowd-to-beat-cancer-seeking-patient-data-to-help-save-lives


Powerful Patients: Highlights and Takeaways from the 2014 Personalized Medicine World Conference

Every year, scientists, doctors, and representatives from pharmaceutical, diagnostics, and technology companies gather in Silicon Valley to talk shop at the Personalized Medicine World Conference (PMWC). For 2 days, they discuss the triumphs and challenges of diagnosing and treating diseases based on patients’ distinct genetic characteristics.

This year, the PMWC status quo was interrupted by a not-so-unlikely guest: the patient. Cancer Commons joined the event’s organizers to cohost a series of informative presentations for patients and advocates, delivered by doctors and researchers, as well as patients and advocates themselves. Continue reading…


Video: Marty Tenenbaum Speaks at Microsoft Research

Cancer Commons founder Marty Tenenbaum, PhD, recently visited Microsoft’s Richmond, CA, office to give a presentation entitled “How to Beat Cancer.”

Because of “a convergence of recent developments in genomics, big data informatics, social networks, and personalized medicine that is transforming the landscape of cancer research and treatment,” Marty says, “we are now on the threshold of being able to give each individual the knowledge, resources, and tools needed to successfully treat the one disease that matters most to them.”

Watch the complete presentation at the Microsoft Research site.


Nature Reviews Clinical Oncology Publishes Paper by Marty Tenenbaum

Today the journal Nature Reviews Clinical Oncology published a paper written by Cancer Commons founder Marty Tenenbaum and co-author Jeff Shrager. The piece discusses the concept of Rapid Learning Precision Oncology. In this approach, every patient receives the best available treatment for them, based on the specifics of their diagnosis. Then the outcomes (e.g., tumor shrinkage, side effects, quality of life, etc.) are used to support and refine the treatment model on which patients’ treatment decisions are based. Tenenbaum and Shrager review the Rapid Learning Precision Oncology approach and the many challenges to its implementation.

Read the article: Rapid learning for precision oncology. Nature Reviews Clinical Oncology. Jan 21, 2014. doi: 10.1038/nrclinonc.2013.244

Please contact us if you are interested in a pdf of the paper.


Cancer Commons Partners with the Melanoma Research Foundation to Launch Online Patient Registry

Today Cancer Commons and the Melanoma Research Foundation announce an online patient registry to advance research for a cure.

For Immediate Release: January 17, 2014

 

The Melanoma Research Foundation and Cancer Commons partner to launch online patient registry to advance research for a cure

Donate Your Data (DYD) is the first platform to collect open-access information that will be made available to patients, physicians and researchers

Washington, DC, and Palo Alto, California, January 17, 2014 – The Melanoma Research Foundation (MRF) and Cancer Commons today announce the launch of the Donate Your Data (DYD) Program, an online registry for melanoma patients and survivors. DYD encourages patients to anonymously share their cancer experiences to advance research and, in return, inform their own clinical care.

Melanoma is one of the fastest growing cancers. With a 1 in 50 lifetime risk of developing melanoma, nearly 77,000 Americans were expected to be diagnosed with the disease in 2013, resulting in over 9,400 deaths.

Through DYD, each melanoma patient records and updates personal disease characteristics in a private, secure online profile. Entries capture stage, treatments, molecular test results, side effects, and treatment responses. All data will be made freely available in de-identified form, giving doctors, researchers, and patients themselves an unprecedented resource to determine the best approaches to melanoma care, according to each patient’s unique clinical history.

“DYD aims to collect data from at least 10% of the approximately 1 million melanoma patients and survivors in the U.S., and even more worldwide,” says Shelby Moneer, Education Program Manager at the MRF. “Our partnership with Cancer Commons is an exciting new facet of our commitment to providing patient resources and supporting research into effective treatments and eventually, a cure for this disease.”

Continue reading…


Cancer Commons to Co-Host First Track for Patients & Advocates at Personalized Medicine World Conference

Personalized oncology is changing the cancer treatment landscape. Increasingly, patients are treated according to the distinct genetics of their tumors. To realize the full benefits of this shift, cancer patients and advocates must be engaged and informed. Cancer Commons has joined the Personalized Medicine World Conference (PMWC) to co-host a special two-day track for cancer patients and advocates. Attendees will have the opportunity to discuss personalized medicine with each other and with researchers, clinicians, and industry leaders. Distinguished speakers will present the latest advances in personalized oncology and discuss its promise for the future.

PMWC is the largest and most established global conference on personalized medicine. It provides a platform for clinical, scientific, industry, and mobile health stakeholders to collaborate and catalyze further change. Cancer patients and advocates can register for the Patient & Advocate Program (Track 4) at a discounted fee.

PMWC 2014 will take place January 27-28, 2014, at the Computer History Museum in Mountain View, CA.